95 related articles for article (PubMed ID: 9085015)
1. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL.
Nuessler V; Scheulen ME; Oberneder R; Kriegmair M; Goebel KJ; Rathgeb F; Wurst W; Zech K; Wilmanns W
Eur J Med Res; 1997 Feb; 2(2):55-61. PubMed ID: 9085015
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
Ramnath N; Schwartz GN; Smith P; Bong D; Kanter P; Berdzik J; Creaven PJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):227-30. PubMed ID: 12655441
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug.
Goedhals L; Bezwoda WR; Abratt RP; Rathgeb F; Goebel KJ; Wurst W
Int J Clin Pharmacol Ther; 1995 Dec; 33(12):664-9. PubMed ID: 8963484
[TBL] [Abstract][Full Text] [Related]
5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
6. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.
Matin K; Egorin MJ; Ballesteros MF; Smith DC; Lembersky B; Day RS; Johnson CS; Trump DL
Cancer Chemother Pharmacol; 2002 Sep; 50(3):179-85. PubMed ID: 12203099
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of vinblastine and verapamil given by concurrent iv infusion.
Benson AB; Trump DL; Koeller JM; Egorin MI; Olman EA; Witte RS; Davis TE; Tormey DC
Cancer Treat Rep; 1985; 69(7-8):795-9. PubMed ID: 4016789
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.
Cairo MS; Siegel S; Anas N; Sender L
Cancer Res; 1989 Feb; 49(4):1063-6. PubMed ID: 2536292
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate.
Zeffren J; Yagoda A; Kelsen D; Winn R
Anticancer Res; 1984; 4(6):411-3. PubMed ID: 6517534
[TBL] [Abstract][Full Text] [Related]
18. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with upper gastrointestinal carcinomas.
Ajani JA
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]